2020
The Clinical Importance of Herb-Drug Interactions and Toxicological Risks of Plants and Herbal Products
https://www.intechopen.com/chapters/71771
Table 1.
고혈압에 대한 허브/천연 제품의 장점과 단점.
Herbal/natural products for evidence of benefit Herbs/herbal products for evidence of harm Causes
Coenzyme Q10 | Ephedra spec. (Ephedra) | Cardiac effects, hypertension, palpitations, tachycardia, stroke, seizures |
Fish oil | Citrus × aurantium L. (Bitter orange) | Blood pressure increases occur in healthy people |
Allium sativum L. (Garlic) | Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Siberian Ginseng) | Hypertension, tachycardia, palpitations |
Vitamin C | Glycyhrriza glabra (Licorice) | Mineralocorticoid excess syndrome, subsequent hypertension |
표 2. 신경학적 부작용을 일으키는 것과 관련된 약초 요법 .
*우리는 식물이나 그 제품의 대략적인 사용을 알고 있지만 표에 있는 일부 식물은 식물 요법에 사용하는 것이 바람직하지 않은 강력한 식물일지라도 일반적으로 중국 전통 의학에서 사용됩니다.
Herbs Adverse effects Potential drug interactions
Panax ginseng C.A.Mey. | Insomnia, vaginal bleeding, mastalgia, mania | Phenelzine, hypoglycemic drugs |
Valeriana officinalis L. (Valerian) | Headache, GI symptoms, hangover | Other CNS depressants |
Datura stramonium (Jimson weed)* | Ataxia, blurred vision, disorientation, other cholinergic signs | Other anti-cholinergic agents |
Glycyrrhiza glabra (Licorice) | Mineral corticoid effects | Antihypertensives, corticosteroids, digoxin |
Passiflora incarnata L. (Passionflower) | Nausea, drowsiness, ventricular tachycardia | Other CNS depressants |
Mentha pulegium L. (Pennyroyale) | GI symptoms and cramps, confusion, hallucination, liver failure | Inhibitors of cytochrome P-450 system |
Piper methysticum G.Forst. (Kava)* | GI symptoms, restlessness, allergies, hepatitis | Other CNS depressants |
Ephedra sinica (Ma Huang)* | Anxiety, confusion, insomnia, psychosis | Other CNS-stimulants, beta-blockers, MAO-inhibitors, phenothiazines, theophylline |
Ginkgo biloba L. | GI symptoms, allergies, headache, dizziness, bleeding | Anticoagulants |
Tripterygium wilfordii (Thunder God Vine)* | Dryness of mouth, nausea, GI symptoms, leukopenia | Not known |
Eucalyptus sp. | Cyanosis, delirium, GI symptoms | Not known |
Hypericum perforatum (St. John’s wort) | GI symptoms, allergies, fatigue, anxiety | Serotonin reuptake inhibitors, hepatic enzyme inducer |
Aconitum sp. (Aconite)* | Acidosis, bradycardia, diarrhea, hypokalemia | Antiarrhythmics, antihypertensives |
Table 4.
심혈관계 치료에 일반적으로 사용되는 일부 허브
Herbs Interacting drugs CYP, P-gp induction/inhibition
Piper longum L. | Verapamil, digoxin, propranolol | CYP3A4, CYP2D6 and CYP1A2 (inhibition) |
Curcuma longa L. | Losartan, rosuvastatin, warfarin, clopidogrel | CYP3A4, CYP1A2, CYP2B6, CYP2C19, CYP2C9 (inhibition) |
Talinolol | P-gp induction, intestinal P-gp in subjects with ABCB1 C3435T genotype inhibition | |
Fucus vesiculosus L. | Amiodarone, valsartan | CYP1A (induction), CYP2C9 (inhibition) |
Zingiber officinale Roscoe | Nifedipine, phenprocoumon | CYP2C9 (potent inhibition) CYP2C19, CYP3A4 (moderate inhibition) |
Terminalia bellirica (Gaertn.) Roxb. | Diltiazem | CYP3A4 CYP2D6 |
Salvia miltiorrhiza Bunge | Warfarin | CYP3A4 (induction) CYP1A2, CYP2C9, CYP1E1, CYP2C6, CYP2C11 (inhibition) |
Allium sativum | Atorvastatin, cilostazol | CYP2C9, CYP3A4 and CYP2D6 (inhibition) P-gp induction |
Ginkgo biloba | Diltiazem, cilostazol | CYP1A2, CYP3A, and CYP2C9 (P-gp inhibition inhibition) CYP2C19 (induction) |
Nifedipine | Unknown | |
Talinolol | Intestinal P-gp inhibition | |
Glycrrhiza glabra | Atorvastatin, simvastatin, lovastatin | CYP2B6, CYP2C9, CYP2C19 (inhibition) CYP3A4 (induction) |
Panax ginseng | Warfarin | CYP3A4 (induction), CYP2C11 (inhibition) |
Nifedipine | CYP3A4 (inhibition) | |
Pueraria montana (Lour.) Merr. var. lobata (Willd.) Sanjappa & Pradeep | Warfarin | CYP 1A2 (induction) CYP2D6, CYP3A4, and OATs (inhibition) |
Citrus paradisi Macfad. | Felodipine | CYP3A4 (inhibition) |
Talinolol | OATP inhibition | |
Aliskiren | OATP2B1 inhibition | |
Atorvastatin | Intestinal CYP3A4 inhibition | |
Lovastatin | Intestinal CYP3A4 inhibition | |
Simvastatin | Intestinal CYP3A4 inhibition | |
Mentha × piperita L. | Felodipine | CYP3A4 (inhibition) |
Hypericum perforatum | Nifedipine | CYP3A4 (induction) |
Verapamil | ||
Digoxin | P-gp induction | |
Talinolol | P-gp induction | |
Phenprocoumon | CYP2C9 induction, CYY3A4 induction | |
Atorvastatin | CYP3A4 induction, P-gp induction | |
Pravastatin | Intestinal CYP3A4 inhibition | |
Simvastatin | CYP3A4 induction, P-gp induction | |
Rosuvastatin | P-gp induction | |
Camellia sinensis (L.) Kuntze. | Digoxin | P-gp induction, digoxin uptake inhibition |
Nadolol | Intestinal OATP1A2 inhibition | |
Rosuvastatin | Intestinal OATP1A2/OATB2P inhibition | |
Malus pumila Mill. | Atenolol | Unknown (possible mediated by OATP function and modulation of intestinal drug uptake) |
Aliskiren | OATP2B1 inhibition | |
Schisandra chinensis (Turcz.) Baill. | Talinolol | P-gp inhibition |
Citrus × sinensis (L.) Osbeck | Aliskiren | OATP2B1 inhibition |
Silybum marianum (L.) Gaertn. | Losartan | CYP2C9 inhibition |
표 5.
인간 대상에서 수행된 화학요법제와의 한약 상호작용 연구
Herbs Cancer drugs Study type Results
Echinacea | Etoposide | Case report | It was found that taking echinacea with etoposide rarely reduced platelet (16 × 103/L) compared to etoposide alone (44 × 103/L) |
Docetaxel | Prospective study in 10 cancer patients | Echinacea did not cause a significant change in the pharmacokinetics of docetaxel | |
Garlic | Docetaxel | Prospective, patient controlled, pharmacokinetic | Garlic was found to reduce docetaxel clearance. Although this reduction is not statistically significant, it can potentially increase side effects due to docetaxel accumulation |
Ginseng | Imatinib | Case report | After receiving ginseng in patients receiving imatinib for 7 years, hepatotoxicity symptoms began to appear. Hepatotoxicity improved upon discontinuation of ginseng |
Grapefruit juice | Docetaxel | Case report | Grapefruit juice has been found to reduce the clearance of docetaxel, while increasing the AUC and terminal half-life of docetaxel |
Nilotinib | Open label, randomized, 2 period crossover | It was found that grapefruit juice increased the AUC and the peak concentration of nilotinib, but did not affect the elimination half-life | |
Milk thistle | Irinotecan | Pharmacokinetic study | It has been found that milk thistle causes a statistically insignificant decrease in irinotecan clearance, which is unlikely to cause a clinical effect |
St John’s wort | Docetaxel | Pharmacokinetic study | St John’s wort was found to cause a significant decrease in plasma docetaxel concentration |
Irinotecan | Unblinded, randomized crossover study | St John’s wort caused a 42% reduction in plasma concentrations of the active metabolite (SN-38) | |
Imatinib | Open-label, crossover pharmacokinetic study | St John’s wort reduced the plasma concentration of imatinib by 32% and reduced the half-life of imatinib by 21% | |
2-period, open-label, fixed sequence study | St John’s wort increased the imatinib clearance by 43% and decreased the plasma concentration by 30% |
표 7.
신부전 환자가 사용하는 약초 및 안전 문제
Herbs Dosage form/ doses associated with safety concernsSafety concerns
Panax ginseng | Crude and standardized Ginseng root extract, high doses, combined preparation | It may hypoglycemic effect and can cause hypertension, as well as may interact with anticoagulants |
Ginkgo biloba | Standardized Ginkgo extract (EGb 761, 80 mg/day), crude Ginkgo plant parts (5 ppm of toxic ginkgolic acid) | It may interact with anticoagulants and can cause a severe allergic reaction |
Cinnamomum cassia (L.) J.Presl | Cinnamon extract | It may have hypoglycemic effect and may cause worsen liver conditions |
Zingiber officinale | Dried root, liquid extract, doses >10 g/day | It may interact with anticoagulants |
Allium sativum | Fresh garlic, dried powder (>7 g/day), higher doses than usual dietary intake | It may interact with anticoagulants, antihypertensive, anti-hyperlipidemic, and hydrochlorothiazide |
Andrographis paniculata (Burm.f.) Nees | Andrographis paniculata extract (50 and 100 mg/kg/day) for 14 days, standardized Andrographis extract | It may interact with hepatic metabolizing enzymes, anticoagulant, antiplatelet, anti-hyperglycemic, barbiturates |
Momordica charantia L. | Bitter melon tea, bitter melon extract administered intravenously and intraperitoneally, high-dose bitter melon seed | It may hypoglycemic effect and may interact with hypoglycemic agents, death in children |
Punica granatum L. | Pomegranate juice, pomegranate extract | It may possibly interact with anticoagulants |
Angelica sinensis (Oliv.) Diels | Dong Quai extract (tablet), dose: 565 mg (1–2 tab/day) for 4 weeks | It may increase the risk of bleeding, increase cancer risk, as well as may interact with anticoagulants, antiplatelet, estrogen (augments the effect of estrogen) |
Medicago sativa L. | Alfalfa seed products | It may cause autoimmune diseases (SLE, multiple sclerosis, rheumatoid arthritis), photosensitivity, estrogen-like and hypoglycemic effects, and may interact with immunosuppressants, warfarin, oral contraceptives, estrogen conjugates, oral hypoglycemic agents, iron, vitamin |
Trigonella foenum-graecum L. | Fenugreek seeds, fenugreek seed powder (>5 g) | It may have a hypoglycemic and estrogen-like effects |
Camellia sinensis | Tea (high dose >600 mg/day or 2.25–4.5 L/day) | It may cause liver problems, and may interact with nadolol (beta-blocker), diuretics |
Morinda citrifolia L. | Noni juice, dose >400 mL | It may cause liver toxicity, and contains high potassium |
Spirulina | A product containing blue-green algae | It may increase the risk of bleeding, may interact with immunosuppressant, antiplatelet, anticoagulants, NSAIDs, other herbs that reduce blood clotting (e.g., ginseng, garlic, ginkgo) |
표 8.
폐경기에 대한 허브와 허브 약물 상호 작용.
Herbs HID
Cimicifuga racemosa | Increase the activity of antihypertensive agents |
Angelica sinensis | Inhibit platelet aggregation and increase risk of bleeding if co-medicated with anticoagulants |
Oenothera biennis L. | Potentially interacts with anti-inflammatory drugs, corticosteroids, beta-blockers, antipsychotics and anticoagulants |
Trifolium pratense L. | Increase the activity of CYP3A4 and alters the metabolism of drugs |
Humulus lupulus L. | Interact with CNS depressants, antipsychotics, hormones and CYP-metabolized drugs |
표 9.
허브-미량 영양소 상호 작용 및 그 메커니즘.
Phytochemicals Micronutrient affectedEffect and interaction mechanisms
Plant polyphenols (PPs) (tea catechins, phloretin, quercetin) | Iron | PPs reduce absorption through complexation |
Folate, ascorbate | PPs reduce absorption through uptake transporter inhibition | |
Silymarins | Iron | They reduce absorption through complexation |
Phytic acid | Calcium, iron, zinc | It reduces absorption through complexation |
Hyperforin (St. John’s wort) | Vitamin D3 | It enhances plasma clearance through induction of CYP3A4 metabolism |
표.10
2018년 '약초에 대해' 데이터베이스에서 액세스한 상위 10개
Common nameScientific name of the plants/dietary supplementsKey interaction and concernsAvoid in
Chaga | Inonotus obliquus (Ach. ex Pers.) Pilát | High in oxalates Anticoagulants Anti-platelets Antihyperglycemic agents |
Renal disease Diabetic patients on treatment (acarbose) |
Turmeric | Curcuma longa | High in oxalates CYP2C9 enzyme |
Renal disease |
Ashwagandha | Withania somnifera (L.) Dunal | Increase testosterone levels in men | Prostate cancer |
Reishi mushroom | Ganoderma lucidum (Curtis) P.Karst. | Anticoagulants Anti-platelets |
Radiation therapy |
Graviola | Annona muricate L. | Antihyperglycemic agents | Diabetic patients on treatment |
AHCC | Active Hexose-Correlated Compound | CYP2D6 enzyme inducer | Breast cancer patients on doxorubicin, zofran, and aromatase inhibitor (letrozole) |
Boswellia | Boswellia serrata Roxb. ex Colebr. | Unknown | Contact dermatitis |
Dandelion | Taraxacum mongolicum Hand.-Mazz., T. officinale (L.) Weber ex F.H.Wigg | CYP1A2 enzyme Diuretic Antihyperglycemic agents Estrogenic activity |
Hormone-sensitive breast cancer |
Green tea | Camellia sinensis | High doses or taken on an empty stomach can cause liver toxicity Bortezomib | Elevated liver function tests |
Turkey tail mushroom | Trametes versicolor (L.) Lloyd | Unknown | Patients on immunosuppressants (in theory) |
표 11.
일부 약초 상호 작용
PlantsEffect and usageDrugsInteractions
Allium sativum | Antihypertensive, antithrombotic, fibrinolytic, antimicrobial, antidiabetic and lipid-lowering properties [20] | Anticoagulant | May lead to increased anticoagulation effect of warfarin and may increase the risk of bleeding [21, 22, 23] |
Antiretroviral (saquinavir) | May decrease the plasma level of protease inhibitor saquinavir [24, 25] | ||
Antidiabetic (metformin, chlorpropamide) | May occur greater reduction in blood glucose level [26, 27] | ||
Paracetamol (acetaminophen) | May change some pharmacokinetic variables of paracetamol [28] | ||
Aloe vera L. | Laxative antidiabetic [20] | Corticosteroids and potassium-depleting diuretics | Laxative and potassium lowering effect may result in hypokalemia [29, 30] |
Cardiac glycosides and antiarrhythmic drugs | May enhance the hypokalemia-related arrhythmia [29, 30] | ||
Antidiabetics | Because of the glucose-lowering effects, diabetic patients should be careful when combining with an antidiabetic agent [31] | ||
Cassia senna L. | Laxative [20] | Corticosteroids and potassium-depleting diuretics | May lead to hypokalemia, since senna can cause excessive water and potassium loss, theoretically [20] |
Digitalis glycosides | Risk of digitalis toxicity due to hypokalemic effect of senna, theoretically [20] | ||
Echinacea purpurea (L.) Moench. | As immunostimulant and in treatment of upper respiratory tract infections [20] | Anabolic steroids, amiodarone (antiaritmic), methotrexate (chemotherapy agent-immunosuppressant), ketoconazole (antifungal), and acetaminophen | The risk of hepatoxicity by concomitant usage of potentially hepatoxic Echinacea [32, 33] |
Immunosuppressants | Might decrease the effects of immunosuppressants, theoretically [34] | ||
Midazolam (benzodiazepine) | May increase oral bioavailability of midazolam or [20] | ||
Ginkgo biloba | To improve cognitive functions, cerebrovascular disorders and vertigo [20] | Phenobarbital | Reduces the therapeutic potency of phenobarbital [35] |
Ibuprofen (NSAID) | May cause fatal intracerebral bleeding [36] | ||
Anticoagulant (warfarin) and antiplatelet (aspirin) drugs | Possible additive inhibition on platelet aggregation [37, 38] | ||
Antidepressant (trazodone) | Ginkgo flavonoids increase the production of 1-(m-chlorophenyl) piperazine (mCPP), an active metabolite of trazodone. Flavonoids and mCPP may induce the enhancement of GABAergic activity [34] | ||
Thiazide diuretic (not specified in the original paper) | Further increase in blood pressure [39] | ||
Nicardipine (a calcium channel blocker) | Decreasing the hypotensive activity of drugs [40] | ||
Nifedipine, diltiazem (calcium channel blockers) and talinolol (β-blocker) | Possible increased antihypertensive activity resulting from high bioavailability [41, 42, 43, 44] | ||
Cyclosporine | Decreased bioavailability of drug [45] | ||
Midazolam (benzodiazepine) | Decreased bioavailability of drug [46] | ||
Propranolol (β-blocker) | Decreased the plasma concentrations of propranolol [47] | ||
Theophylline | Less efficacy with Ginkgo [48] | ||
Omeprazole (proton pump inhibitor) | May induce the metabolism, and reduce the effect of omeprazole [49] | ||
Tolbutamide (an antidiabetic drug) | May increase or decrease the hypoglycemic effect of tolbutamide [50] | ||
Amikacin (aminoglycoside) | Amikacin ototoxicity may enhance [51] | ||
Glycyrrhiza glabra | Expectorant, antispasmodic and anti-inflammatory properties and in treatment of peptic and duodenal ulcers [20] | Prednisolone (corticosteroid) | Glycyrrhizin increases the plasma concentrations and potentiates pharmacological effects of prednisolone [52, 53] |
Hydrocortisone (corticosteroid) | Glycyrrhetinic acid potentiates the activity the topical cutaneous vasoconstrictor effect [54] | ||
Dexamethasone (corticosteroid) | Dexamethasone induces the mineralocorticoid effects of glycyrrhizin [55] | ||
Antihypertensives | Mineralocorticoid effects (sodium and water retention and hypokalemia) of plant reduce the efficacy of the drugs that use to lower blood pressure. Hypokalemic effect of the plant may increase the effect of the loop and thiazide diuretics [20] | ||
Hypericum perforatum | To treat depression, seasonal affective disorder, anxiety and insomnia, especially related to menopause [20] | Gliclazide (an antidiabetic drug) | Increases the apparent clearance of gliclazide [56] |
Carbamazepine, phenytoin and phenobarbital (antiepileptics) | Clinically significant interaction is unlikely, but Hypericum should be used carefully with these antiepileptic drugs [20] | ||
Alprazolam, midazolam, triazolam and quazepam (benzodiazepines) | Since the main compound hyperforin induces the enzyme CYP3A4, bioavailability may decrease [20, 57] | ||
Indinavir (protease inhibitor) Nevirapine (nonnucleoside reverse transcriptase) |
May decrease the antiretroviral drugs and may lead to development of drug resistance [58, 59] | ||
Cyclosporine, tacrolimus, (Immunosuppressants) | May decrease the blood levels and may lead the acute organ rejection in transplant patients [60, 61, 62] | ||
Warfarin and phenprocoumon (anticoagulants) | May cause a moderate reduction in the anticoagulant effects of the drugs [20] | ||
Simvastatin and atorvastatin (antihyperlipidemic agents) | May observe the increasing serum level of total cholesterol [63, 64] | ||
Nifedipine, verapamil (calcium channel blockers) and talinolol (a β-adrenoceptor blocker) | May decrease the bioavailability of drugs [65] | ||
Oral contraceptives | Associated with increased metabolism of ethinyl estradiol, norethindrone, and ketodesogestrel, and may cause bleeding and unwanted pregnancy [66, 67, 68, 69] | ||
Carbamazepine (antiepileptic) | Should be considered a mild interaction between carbamazepine and Hypericum | ||
Sertraline, nefazodone (selective serotonin reuptake inhibitors) | May be occurred the symptoms of central serotonergic syndrome [70] | ||
Linum usitatissimum L. | Demulcent for bronchitis and coughs, and topically used for burns [20] | Anticoagulant or antiplatelet drugs | In the view of the thought that omega-3 fatty acids such as linolenic acid have antiplatelet effects, should be concerned about the possibility of prolonged bleeding [20] |
Panax ginseng | Adaptogenic [20] | Phenelzine (MAO inhibitor) | Additive nervous system effect of drug such as headache, tremor, sleeplessness and mania [34] |
Warfarin (anticoagulant) | INR may decrease by concomitant usage [71] | ||
Warfarin, heparin, aspirin, and NSAIDs | There is no clear data, but due to the antiplatelet components in P. ginseng, it should be avoided concomitant using [32] | ||
Caffeine | Possible additive stimulant effects [20] | ||
Piper methysticum | Anxiolytic, sedative, aphrodisiac | Barbiturates and benzodiazepines | Might potentiate the effects of central nervous system depressants [72] |
Alprazolam (benzodiazepine) | Risk of coma due to possible additive effect on GABA receptor [72] | ||
Levodopa | May reduce the efficacy due to possible dopaminergic antagonism [73] | ||
Acetaminophen | May enhance the risk of hepatotoxicity [33] | ||
Valeriana officinalis | Used for stress and insomnia as sedative and anxiolytic [20] | Barbiturates | Excessive sedation. The active component valerenic acid seems to likely to have the additive effect to phenobarbital [74] |
Other central nervous system depressants such as benzodiazepines and opioids | Possible additive sedative effects [20] | ||
Caffeine | Possible reverse effect to the sedative effect of Valerian [20] | ||
Zingiber officinale | To reduce nausea and emesis induced by pregnancy, chemotherapy, and postoperative ileus [75] | NSAIDs | May reduce the platelet aggregation and enhance the bleeding tendency [33] |
Nifedipine | May potentiate the antiplatelet effects [76] | ||
Metronidazole | May increase the bioavailability [77] | ||
Glibenclamide (antidiabetic) | May reduce the blood glucose level [26] |
***************************************************************
'약물' 카테고리의 다른 글
건강 보조 식품과 잠재적인 약물 상호 작용 (0) | 2022.09.23 |
---|---|
허브-약물 상호작용: 임상 증거 개요 (0) | 2022.09.23 |
허브와 일반약들 간의 상호 작용: 임상 데이터 개요 (0) | 2022.09.23 |
허브-약물 상호 작용: 개요 (0) | 2022.09.23 |
흔한 허브 식이 보조제-약물 상호 작용 (0) | 2022.09.23 |